Sylvester Research Highlights: ASCO 2023
This year’s American Society of Clinical Oncology conference will feature five researchers who present new thoughts on cancer treatment, global health equity and patient quality of life.
Five researchers from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, will be highlighted at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting for their work in groundbreaking clinical research.
The meeting, which attracts more than 40,000 attendees, takes place in Chicago June 2-6 and will offer oncology professionals a unique opportunity to connect at one of the largest events in global cancer care.
Zoukaa B. Sargi, M.D., M.P.H., professor of otolaryngology and neurosurgery and director of the residency program in the Department of Otolaryngology, will be part of a panel at ASCO providing the surgeon’s perspective on controversies in the management of advanced thyroid cancer. Together with an endocrinologist and medical oncologist from other institutions,
Dr. Sargi will discuss the new treatment options available to patients.
Shria Kumar, M.D., M.S.C.E., clinical epidemiologist and gastroenterologist at the University of Miami Miller School of Medicine and researcher with Sylvester Comprehensive Cancer Center, has been awarded a Conquer Cancer Career Development Award.
Gilberto Lopes, M.D., chief of the Division of Medical Oncology and associate director for global oncology at Sylvester will highlight his and others’ work with the Access to Oncology Medicines (ATOM) Coalition, a global initiative established by the Union for International Cancer Control and partners like Sylvester. His talk is titled, “The Potential for Using the ATOM Model to Impact Cancer Mortality in Low- and Lower Middle-Income Countries.”
Macarena de la Fuente, M.D., Sylvester associate professor of neurology, chief of neuro-oncology and co-chair of the Society for Neuro-Oncology’s Women and Diversity Committee, will present results from a Phase 1/2a study showing the experimental, targeted therapy may be effective in treating BRAF-altered solid tumors, including mutations not previously targeted with a benign safety profile.
Kristin Rojas, M.D., FACS, assistant professor of surgical oncology at Sylvester Comprehensive Cancer Center and the Dewitt Daughtry Department of Surgery at the University of Miami Miller School of Medicine will speak about the risks posed by endocrine therapies, define symptoms and discuss treatment options in her presentation titled, “Better Sexual Health for Female Patients on Endocrine Therapy: Strategies Across the Age Spectrum.”